PASC - Meeting 12-13 April 2018

Page last updated: 16 April 2018

PICO Advisory Sub-Committee - Applications Considered

1495 - Somatic tumour gene panel test

1512 - Apolipoprotein B testing for high risk cardiovascular disease risk assessment

1518 - Endoscopic non-contact (side firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)

1519 - Tisagenlecleucel (CTL019, chimeric antigen receptor T cell: CAR-T therapy) for treatment of refractory CD19-positive leukaemia and lymphoma

1522 - PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma

1524 - Expanding the BRAF testing MBS item to include patients with resectable Stage III melanoma (co-dependent)

1525 - Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer

1526 - Somatic tumour gene testing for the diagnosis of Diffuse Large B Cell Lymphoma, Multiple Myeloma and Non-Hodgkin Lymphoma Subtypes

1527 - Somatic tumour gene testing for the diagnosis of Gliomas, Gliobastomas, and Soft Tissue and Bone Tumours

1528 - Somatic tumour gene testing for the diagnosis of renal cell carnicoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast

1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)